Oxford Immunotec Global (OXFD) Issues Quarterly Earnings Results

Oxford Immunotec Global (NASDAQ:OXFD) announced its quarterly earnings results on Friday. The company reported ($0.24) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.14), Morningstar.com reports. The company had revenue of $16.10 million during the quarter, compared to analysts’ expectations of $33.60 million. Oxford Immunotec Global had a negative net margin of 23.41% and a negative return on equity of 39.85%. The business’s revenue for the quarter was up 7.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.70) earnings per share.

Shares of OXFD stock traded down $0.09 during trading hours on Friday, hitting $15.67. The stock had a trading volume of 4,846 shares, compared to its average volume of 135,338. The company has a market capitalization of $396.01 million, a P/E ratio of -11.57 and a beta of -0.09. Oxford Immunotec Global has a twelve month low of $10.00 and a twelve month high of $19.19. The company has a current ratio of 5.39, a quick ratio of 4.86 and a debt-to-equity ratio of 0.41.

In related news, CEO Peter Wrighton-Smith sold 86,100 shares of the stock in a transaction on Tuesday, September 25th. The stock was sold at an average price of $18.42, for a total transaction of $1,585,962.00. Following the completion of the sale, the chief executive officer now directly owns 539,569 shares of the company’s stock, valued at $9,938,860.98. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Richard A. Sandberg sold 3,000 shares of the stock in a transaction on Thursday, November 1st. The stock was sold at an average price of $15.50, for a total value of $46,500.00. Following the sale, the director now directly owns 9,000 shares of the company’s stock, valued at $139,500. The disclosure for this sale can be found here. Insiders sold 149,100 shares of company stock valued at $2,564,662 over the last three months. Corporate insiders own 6.61% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. lifted its holdings in shares of Oxford Immunotec Global by 19.7% during the second quarter. Russell Investments Group Ltd. now owns 97,445 shares of the company’s stock worth $1,257,000 after purchasing an additional 16,070 shares during the period. Bank of Montreal Can acquired a new stake in shares of Oxford Immunotec Global during the second quarter worth $132,000. BlackRock Inc. lifted its holdings in shares of Oxford Immunotec Global by 10.0% during the second quarter. BlackRock Inc. now owns 1,279,324 shares of the company’s stock worth $16,490,000 after purchasing an additional 116,814 shares during the period. Spark Investment Management LLC lifted its holdings in shares of Oxford Immunotec Global by 45.1% during the second quarter. Spark Investment Management LLC now owns 144,100 shares of the company’s stock worth $1,857,000 after purchasing an additional 44,800 shares during the period. Finally, Penn Capital Management Co. Inc. lifted its holdings in shares of Oxford Immunotec Global by 20.4% during the second quarter. Penn Capital Management Co. Inc. now owns 257,026 shares of the company’s stock worth $3,313,000 after purchasing an additional 43,477 shares during the period. 92.40% of the stock is owned by hedge funds and other institutional investors.

Several equities research analysts have recently weighed in on OXFD shares. BidaskClub downgraded Oxford Immunotec Global from a “sell” rating to a “strong sell” rating in a report on Friday, July 20th. ValuEngine downgraded Oxford Immunotec Global from a “hold” rating to a “sell” rating in a report on Tuesday, July 24th. Finally, Zacks Investment Research raised Oxford Immunotec Global from a “hold” rating to a “buy” rating and set a $16.00 price objective for the company in a report on Friday, August 3rd. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $16.67.

ILLEGAL ACTIVITY WARNING: “Oxford Immunotec Global (OXFD) Issues Quarterly Earnings Results” was first published by WKRB News and is the property of of WKRB News. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://www.wkrb13.com/2018/11/09/oxford-immunotec-global-oxfd-issues-quarterly-earnings-results.html.

About Oxford Immunotec Global

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology.

Featured Story: How to Use a Moving Average for Trading 

Earnings History for Oxford Immunotec Global (NASDAQ:OXFD)

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply